en · de · es · pt
epitalon-notes.peptides8425.com › Info › Research Claims And Evidence Status — Field Notes

Research Claims And Evidence Status — Field Notes

By Editorial Desk · published 2026-06-05 · last reviewed 2026-07-23 · Info

epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

Identity and Research Background

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon at a glance

PropertyValueNotes
Regulatory statusNot an approved drugMarketed in most countries as a research chemical
Main literature languageRussian and EnglishEarly reports concentrated in Russian journals
Typical stated purity≥95% by HPLCSupplier declaration, seldom independently verified
Principal studied endpointTelomerase activity in vitroMeasured in cultured human cells
Reported administration routesSubcutaneous, intranasalDescribed in exploratory use reports

Stability Handling and Quality Control

Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.

Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.

Related pages on this site

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Analytical Characterization and Stability

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.

Background and Proposed Mechanism

Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Supporting material

=== Fabrication and misrepresentation === As early as 2000, Hari was criticised by Ben Elton in the letters page of Varsity for inaccuracies including stating that only Jews can be Israeli citizens. In addition to plagiarism, Hari was found to have fabricated elements of stories. In one of the stories for which he won the 2008 Orwell Prize, he reported on atrocities in the Central African Republic, stating that French soldiers told him that "Children would bring us the severed heads of their parents and scream for help, but our orders were not to help them." However, an NGO worker who translated for Hari said that the quotation was invented and that Hari exaggerated the extent of the devastation in the CAR. In his apology after his plagiarism was exposed, Hari said that other staff of the NGO had supported his version of events. In a 2010 article about military robots, Hari falsely claimed that former Japanese prime minister Junichiro Koizumi was attacked by a factory robot and was nearly killed. Hari falsely claimed that a large globe erected for the Copenhagen climate summit was "covered with corporate logos" for McDonald's and Carlsberg, with "the Coke brand ... stamped over Africa".

Other compounds other than radiolabelled somatostatin receptor antagonists have also been studied. Cyclosomatostatin is one such compound. Contrary to previously discussed compounds, cyclosomatostatin does not contain a radionuclide. It is a non-selective somatostatin receptor antagonist, inhibiting the effects of somatostatin on target cells in the gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS). Cyclosomatostatin is used as a research chemical to investigate the effects of somatostatin on different cell types by antagonizing its receptors. However it acts as an agonist in SH-SY5Y neuroblastoma cells. Cyclosomatostatin is also known by the following names:

In 2015, Schumer was named one of Time magazine's 100 most influential people. Schumer was named to Barbara Walters' 10 Most Fascinating People for 2015. Schumer has received praise for addressing various social issues through comedy. Throughout 2015, several of Schumer's skits in Inside Amy Schumer went viral online, sparking editorials regarding sex, feminism, and rape culture. In June 2015, Monica Heisey of The Guardian criticized her for "a shockingly large blind spot around race". Schumer responded on Twitter, stating "I go in and out of playing an irreverent idiot. That includes making dumb jokes involving race ... You can call it a 'blind spot for racism' or 'lazy,' but you are wrong. It is a joke ... I am not racist." Schumer was again criticized in July 2020 by Kyndall Cunningham of The Daily Beast for her earlier work, which included "objectifying black men" and calling Latina women "crazy". Cunningham described her "sudden" decision to support the Black Lives Matter movement as "befuddling and laughable". After a fatal shooting took place at a showing of Trainwreck in Louisiana, Schumer advocated for stricter gun control laws and increased mental health funding. After her 2018 wedding, Schumer asked fans to donate to Everytown for Gun Safety instead of giving wedding gifts. In November 2015, Schumer posed nude for a photo by photographer Annie Leibovitz for the 2016 edition of the Pirelli Calendar. Schumer tweeted the photo, writing "Beautiful, gross, strong, thin, fat, pretty, ugly, sexy, disgusting, flawless, woman.

Sources: en.wikipedia.org

Notes from published material

== Evolution == Many scientific studies throughout the past half century have used porcine aminoacylase as their model aminoacylase enzyme. The amino acid sequence and primary structure of porcine aminoacylase have been determined. Porcine aminoacylase 1 is composed of two identical heterodimeric subunits each consisting of 406 amino acids, with acetylalanine at the N-terminus of each. Porcine aminoacylase differs from human aminoacylase in structure but replicates its function. It can be inferred from this data that these two enzymes evolved from a common ancestral protein, retaining function but diverging in structure over time.

=== Production === Generators provide radiation shielding for transport and to minimize the extraction work done at the medical facility. A typical dose rate at 1 metre from 99mTc generator is 20–50 μSv/h during transport. These generators' output declines with time and must be replaced weekly, since the half-life of 99Mo is still only 66 hours. Since the half-life of the parent nuclide (99Mo) is much longer than that of the daughter nuclide (99mTc), 50% of equilibrium activity is reached within one daughter half-life, 75% within two daughter half-lives. Hence, removing the daughter nuclide (elution process) from the generator ("milking" the cow) is reasonably done as often as every 6 hours in a 99Mo/99mTc generator.

SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium/glucose cotransporter 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.

Carbohydrate macromolecules (polysaccharides) are formed from polymers of monosaccharides. Because monosaccharides have multiple functional groups, polysaccharides can form linear polymers (e.g. cellulose) or complex branched structures (e.g. glycogen). Polysaccharides perform numerous roles in living organisms, acting as energy stores (e.g. starch) and as structural components (e.g. chitin in arthropods and fungi). Many carbohydrates contain modified monosaccharide units that have had functional groups replaced or removed.

Sources: en.wikipedia.org

Frequently asked questions

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

What is the strongest evidence for its activity?

The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.

Why is epitalon sold online?

It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.

What is epitalon?

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.

Network